Generic Name and Formulations:
Methoxsalen 10mg; soft gel caps.
Valeant Pharmaceuticals, Inc
Indications for OXSORALEN-ULTRA:
Symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy.
Give only in conjunction with a schedule of controlled doses of long wave UV radiation. Do not sunbathe during the 24hr period prior to methoxsalen ingestion; avoid sun exposure for at least 8hrs after and do not sunbathe for 48hrs after. Wear UVA absorbing wrap-around sunglasses for 24hrs after. Apply sunscreen if sun exposure unavoidable; do not apply to areas affected by psoriasis until after UVA treatment. Give 1½–2hrs before UVA exposure with low fat food or milk. <30kg: 10mg. 30–50kg: 20mg. 51–65kg: 30mg. 66–80kg: 40mg. 81–90kg: 50mg. 91–115kg: 60mg. >115kg: 70mg. See literature for UVA exposure schedule.
Idiosyncratic reactions to psoralen compounds. History of light sensitive disease states (eg, lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism). Melanoma or history of. Invasive squamous cell carcinomas. Aphakia.
Should be used only by experienced physicians. Not interchangeable with regular Oxsoralen or 8-MOP capsules.
To be used only by physicians with special training in photochemotherapy. Do not use interchangeably with Oxsoralen. Increased risk of ocular damage (eg, cataracts), aging of the skin, and skin cancer; monitor. Basal cell carcinoma. Previous radiation or aresenic therapy. Hepatic insufficiency. Cardiovascular disease. Perform ophthalmologic exam prior to start of therapy and then yearly. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Caution with concomitant photosensitizing agents (eg, anthralin, coal tar, griseofulvin, phenothiazines, nalidixic acid, fluoroquinolones, halogenated salicylanilides, sulfonamides, tetracyclines, thiazides, certain organic staining dyes).
Nausea, nervousness, insomnia, depression; combined methoxsalen/UVA therapy: pruritus, erythema, edema, dizziness, headache, malaise, hypopigmentation, vesiculation, bullae formation, rash, herpes simplex, miliaria, urticaria, folliculitis, cutaneous tenderness, leg cramps, hypotension, extension of psoriasis.
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years